🟢 Telix Pharmaceuticals is trading 4.93% up in after-hours trading despite concerns over proposed ITM acquisition dilution

Telix Pharmaceuticals is trading at $11.83, up 4.93%, after regular-session losses tied to investor concerns about its proposed ITM acquisition.

• The US$1.65 billion transaction includes approximately US$1.25 billion in newly issued Telix shares.
• ITM shareholders are expected to receive about 23.7% of the combined company. Reuters and Bloomberg reported the stock-funded structure; coverage described dilution as the central investor concern.